Replies to post #136520 on Biotech Values

[jq1234]

I don't fault them for trying different dosing for CRPC. But for other tumor types, MBC, MTC, GB, HCC, RCC, OC, etc, they have used 175, 140, 125, 100 mg/day. XL184 maybe unique, it isn't this unique. They need to establish a set dosing schedule, and proper dose reduction schedule. Does 140 mg really differ from 125 mg efficacy wise in RCC? I highly doubt it.